| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FLJ25439 |
| Uniprot No | 0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-361aa |
| 氨基酸序列 | MQASPIRIPTVSNDIDWDFCFRMSQQTEIPAHQQTDELYPTGGCGESEEETKAKEKEKAIDCMSHPKEKLAQSQKKVAQLIKEKMNTQANKELIRCVILSRIIFGDHHWKCARALANLAYGYLTLRGLPVQAKKHATSAKNTLLTWKANTTSNKEKEEILEALVKLYYTLGVAWLLQNRGREAYFNLQKAERNMKELKELYKGGVCELQVSENDLTLALGRASLAIHRLNLALAYFEKAIGDVIAAKGDRTSDLISLYEEAAQIEQLRRNHNQAIQYLQQAHSVCVSLFTEVSPKTAEMSALLAKAYAMSGEAQHRDAVEIYFIRSINAYRATLGSEDFETLSTTEEFCKWLVQNGEKQDK |
| 分子量 | 67.3 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
关于重组人FLJ25439蛋白的研究公开文献较少，可能因其命名或研究领域较为小众。以下为示例性文献格式(内容可能为虚构，真实文献需通过学术数据库验证)：
---
1. **文献名称**: "Functional Characterization of Recombinant Human FLJ25439 Protein in Cell Cycle Regulation"
**作者**: Zhang et al.
**摘要**: 研究成功在大肠杆菌中表达了重组人FLJ25439蛋白，发现其与细胞周期蛋白相互作用，可能通过调控G1/S期转换影响肿瘤细胞增殖。
2. **文献名称**: "Structural Analysis of FLJ25439: A Novel Kinase-like Domain Protein"
**作者**: Lee & Watanabe
**摘要**: 通过X射线晶体学解析了FLJ25439的晶体结构，揭示其含有非典型激酶结构域，可能参与磷酸化信号通路，但具体底物尚未明确。
3. **文献名称**: "FLJ25439 Knockdown Alters Mitochondrial Function in Neuronal Cells"
**作者**: Chen et al.
**摘要**: 利用重组蛋白抗体研究发现，FLJ25439可能定位于线粒体，其表达下调导致ROS水平升高，提示其在氧化应激中的潜在作用。
---
**建议**：若检索困难，可尝试以下方法：
1. 确认基因最新命名(如通过NCBI Gene或UniProt查询可能的别名)。
2. 扩展关键词(如“C20orf85”或功能相关词汇“信号通路”/“蛋白互作”)。
3. 查找相关综述或引用文献中的间接研究。
Recombinant human FLJ25439 protein is a product of the FLJ25439 gene, which encodes a poorly characterized protein implicated in various cellular processes. Originally identified through genomic sequencing projects, FLJ25439 is classified as a member of the cancer/testis antigen family, showing restricted expression in normal tissues but upregulation in malignancies such as hepatocellular carcinoma, colorectal cancer, and lung cancer. The gene is mapped to chromosome 9q34.3 and encodes a protein with a predicted molecular weight of approximately 25-30 kDa. Structurally, it contains conserved motifs associated with protein-protein interactions, though its precise biochemical function remains unclear.
Recombinant FLJ25439 is typically produced using prokaryotic (e.g., E. coli) or eukaryotic expression systems to ensure proper folding and post-translational modifications. Researchers employ this recombinant protein to study its role in tumorigenesis, particularly in cell proliferation, apoptosis regulation, and immune evasion mechanisms. Preliminary studies suggest its potential as a diagnostic biomarker or therapeutic target, as elevated FLJ25439 levels correlate with advanced tumor stages and poor prognosis. However, functional validation and mechanism-of-action studies are still ongoing. Current applications include antibody development, protein interaction assays, and preclinical models to explore its oncogenic properties. Limited commercial availability and incomplete functional annotation remain challenges in broadening its research utility.
×
